ProShares Trust - ProShares VIX Short-Term Futures ETF
VIXY
Get informed when a big investor buys or sells
+ FollowShare Statistics
| Market cap | $27.84 Billion |
|---|---|
| Enterprise Value | $27.66 Billion |
| Dividend Yield | $- (NaN%) |
| Earnings per Share | $- |
| Beta | -2.33 |
| Outstanding Shares | - |
Return
| Return on Equity | -25.93% |
|---|---|
| Return on Assets | -23.92% |
| Return on Invested Capital | -27.36% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2118.55 |
| Enterprise Value to EBIT | -368.05 |
| Enterprise Value to Net Income | -393 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7748▼ 101.68% |
|---|---|
| Total Calls | 722,025▲ 120.48% |
| Total Puts | 559,450▼ 4.64% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 16.88%▲ 3.69% |
|---|---|
| Total Invested | $40.95M▲ 36.80% |
| Investors Holding | 51▲ 4.00% |
ESG Score
No data
About BioAge Labs, Inc.
62 employees
CEO: Dr. Kristen Fortney Ph.D. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...
Relevant Senate Committees
This committee controls taxation, trade, and entitlement spending, including Medicare and Medicaid. Its decisions on corporate tax policy and drug reimbursement rates (especially for drugs targeting older adults) directly affect BioAge Labs' future profitability and market access.
This committee directly allocates federal discretionary spending, including budgets for critical agencies like the FDA and NIH. Its funding decisions profoundly impact the regulatory environment and research ecosystem for biopharmaceutical companies.
This committee's regulation of the FDA and NIH is paramount. The FDA's drug approval process is the primary determinant of whether BioAge's products can reach the market, making this committee a direct and critical influence.
This committee oversees intellectual property law, which is critical for biopharmaceutical companies like BioAge Labs to protect their drug discoveries and development efforts. Antitrust oversight is also relevant for future M&A.